Beam Therapeutics (BEAM) vs Vir Biotechnology (VIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Vir Biotechnology (VIR) has outperformed Beam Therapeutics (BEAM) over the past year, gaining 103.5% versus a loss of 1.4%. Over five years, VIR leads with a -70.5% price change compared with -73.4% for BEAM. Beam Therapeutics is the larger company by market cap ($2.56 billion vs $1.95 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BEAM | VIR |
|---|---|---|
| Share price | $24.77 | $11.52 |
| Market cap | $2.56B | $1.95B |
| 1-day change | -1.82% | -0.69% |
| YTD return | -10.64% | +91.04% |
| 1-year return | -1.43% | +103.53% |
| 5-year return | -73.41% | -70.53% |
| EPS (TTM) | $-0.68 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.26 | $11.94 |
| 52-week low | $20.23 | $4.82 |
| Distance from 52-week high | -35.26% | -3.52% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +110.54% | +80.38% |
| Average volume | 1.94M | 1.87M |
| Shares outstanding | 103.29M | 169.22M |
| Employees | 540 | 367 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VIR has outperformed BEAM by 105.0 percentage points over the past year.
About Beam Therapeutics
BEAM stock →Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 540 employees
About Vir Biotechnology
VIR stock →Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees
BEAM vs VIR FAQ
Which is bigger, Beam Therapeutics or Vir Biotechnology?
Beam Therapeutics (BEAM) is larger, with a market capitalization of $2.56B compared with $1.95B for Vir Biotechnology (VIR).
Which stock has performed better over the past year, BEAM or VIR?
VIR returned +103.53% over the past 12 months, compared with -1.43% for BEAM (price return, excluding dividends). Past performance does not predict future results.
Are Beam Therapeutics and Vir Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.